Abbott Expands Lingo Bio-wearables Line From Measuring Glucose To Ketone, Lactate, Alcohol
Executive Summary
Abbott announced at CES 2022 it is developing a line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year.
You may also be interested in...
Abbott’s Lingo Biowearable For Consumers Debuts In The UK As Libre Momentum Continues
Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.
Abbott Speaks Lingo Wearables For Future Growth, Posts Formula As Current Consumer Sales Driver
Lingo’s target “is to do something that not a lot of well-established health care companies do, which is to create a product that's really targeting a healthy population and a healthy population that wants to stay healthy,” says CEO Robert Ford.
HBW Insight’s Key Takeaways From 2021: #3 Keep Your Eye On AI
The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.